STK16-IN-1, a pyrrolonaphthyridinone compound, only potently inhibited STK16 (relative activity remaining 0.65%) and mTOR (relative activity remaining 0.4%) at a concentration of 10 μM.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | mTOR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.